ESPR
NASDAQ
US
Esperion Therapeutics, Inc. - Common Stock
$2,61
▲ +$0,00
(+0,00%)
Vol. 5.8M
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$884.5M
ROE
-59,5%
Margine
-34,8%
D/E
0,00
Beta
1,10
52W
$1–$4
Consenso Wall Street
14 analisti · Apr 20263
Acquisto forte
8
Compra
2
Mantieni
1
Vendi
0
Vendita forte
78,6%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 25,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $0,25 | $0,22 | $-0,03 |
| Set 2025 | $-0,06 | $-0,16 | $-0,10 |
| Giu 2025 | $-0,15 | $-0,02 | +$0,13 |
| Mar 2025 | $-0,16 | $-0,21 | $-0,05 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $69.1M | $65.0M | $82.4M | $87.3M | $168.4M |
| Utile netto | — | -$21.3M | -$40.5M | -$12.7M | -$31.3M | $61.8M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -59.5% | -59.5% | -59.5% | -59.5% | -59.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -15.4% | -38.8% | -38.8% | -38.8% | -34.8% | -34.8% |
| Gross Margin | 65.3% | 61.6% | 61.6% | 61.6% | 58.2% | 58.2% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.15 | 1.15 | 1.15 | 1.15 | 1.00 | 1.00 |
Rapporti chiave
ROA (TTM)
-30,7%
P/S (TTM)
2,91
P/B
81,9
EPS (TTM)
$-0,54
CF/Share
$-2,23
Crescita ricavi 3A
+61,8%
52W High
$4,13
52W Low
$0,69
$0,69
Intervallo 52 settimane
$4,13
Salute finanziaria
Flusso di cassa libero
$45.2M
Debito netto
$84.4M
Liquidità
$167.9M
Debito totale
$252.2M
Aggiornato al Dic 31, 2025
Як ESPR виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка ESPR vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
2,9
▼
41%
sotto
peer
(5,0)
vs Peer
vs Settore
Sottovalutato
P/B
81,9
▲
3763%
sopra
peer
(2,1)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ESPR vs аналоги Pharmaceuticals
ROE
-59,5%
▼
10%
sotto
peer
(-54,3%)
vs Peer
vs Settore
In linea
Net margin
-34,8%
▲
26%
sopra
peer
(-47,4%)
vs Peer
vs Settore
Debole
Валова маржа
58,2%
▼
15%
sotto
peer
(68,3%)
vs Peer
vs Settore
Debole
ROA
-30,7%
▲
18%
sopra
peer
(-37,4%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя ESPR vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
sotto
peer
(1,5)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
1,0
▼
70%
sotto
peer
(3,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,1
▲
17%
sopra
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ESPR
ESPR
Mediana peer
Industria
ESPR прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ESPR vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
HALLADAY BENJAMIN
Chief Financial Officer · Mar 17
6424 shs
KOENIG SHELDON L
Chief Executive Officer · Mar 17
25578 shs
LOOKER BENJAMIN
Officer · Mar 17
5708 shs
KOENIG SHELDON L
Chief Executive Officer · Mar 13
723760 shs
LOOKER BENJAMIN
Officer · Mar 13
300840 shs
HALLADAY BENJAMIN
Chief Financial Officer · Mar 13
247430 shs
LOOKER BENJAMIN
General Counsel · Gen 20
1689 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 23,71%Blackrock Inc.
6,89%
$48.4M
Vanguard Group Inc
5,82%
$41.0M
Two Seas Capital Lp
4,63%
$32.6M
Wasatch Advisors LP
3,68%
$25.9M
Shaw D.E. & Co., Inc.
2,69%
$18.9M
Aggiornato al Dic 31, 2025